Experimental drug combo tested for tough prostate cancer
NCT ID NCT00183937
First seen May 26, 2026 · Last updated Jun 21, 2026 · Updated 3 times
Summary
This study tested a combination of two drugs, bortezomib and docetaxel, in 15 men with advanced prostate cancer that had stopped responding to hormone therapy. The goal was to see if the drugs could lower PSA levels and ease pain. The trial was terminated early, so the findings are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bortezomib (Velcade) and docetaxel
What this could lead to
If successful, this combination could offer a new treatment option for men with advanced prostate cancer that no longer responds to hormone therapy.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. The combination may cause serious side effects and may not improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.